Related Experiment Video
Updated: Aug 5, 2026

Murine Kidney Transplant Technique
Published on: October 20, 2015
Thrombotic Microangiopathy After Kidney Transplantation Associated With Rifampicin: A Case Report
Agatha Prado de Lima1, Diogo Buarque Cordeiro Cabral1, Alexandre de Holanda Cavalcanti Pinto1
1Department of Nephrology and Kidney Transplantation at the Real Hospital Português de Beneficência em Pernambuco, Recife, Pernambuco State, Brazil.
Abstract:
Thrombotic microangiopathy (TMA) is a severe complication, particularly after kidney transplantation (KT), and is associated with significant morbidity, mortality and graft loss. Rifampicin (RIF), although rarely reported, has relevant interactions and may act as an additional trigger capable of precipitating TMA in susceptible patients. Diagnosis requires a high index of suspicion, exclusion of alternative causes and thorough investigation. Considering its prognostic impact on both graft and patient outcomes, identifying RIF as a potential causative agent is essential to guide clinical management, with immediate drug withdrawal being the most appropriate intervention. This case report aims to describe a case of TMA after KT associated with RIF use, given its clinical relevance and the scarcity of available reports.
Insights
Thrombotic microangiopathy (TMA) is a serious risk after kidney transplantation (KT). Rifampicin (RIF) can trigger TMA in susceptible patients, necessitating prompt drug withdrawal for better outcomes.
Area of Science:
- Nephrology
- Pharmacology
- Transplantation Medicine
Background:
- Thrombotic microangiopathy (TMA) is a severe complication post-kidney transplantation (KT).
- TMA is linked to high rates of morbidity, mortality, and graft loss.
- Rifampicin (RIF) is a rarely reported but potential trigger for TMA in susceptible individuals.
Related Concept Videos
Acute Kidney Injury I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction